Skip to content

Exploring epigenetic anti-cancer agents from oriental traditional medicines and elucidation of their mechanism

Exploring epigenetic anti-cancer agents from oriental traditional medicines and elucidation of their mechanism - Exploring epigenetic anti-cancer agents from oriental traditional medicines and elucidation of their mechanism

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000044573
Enrollment
Unknown
Registered
2021-06-25
Start date
2020-04-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteer

Interventions

None listed

Sponsors

Chiba university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age: 20 years and over 2) Agreement to a doctor's interview regarding health condition. 3) Systolic blood pressure is 90-160 mmHg and diastolic blood pressure is 100 mmHg or less 4) Weight: men 45 kg or more, women 40 kg or more 5) After receiving sufficient explanation for participation in this study, written consent by free will have been obtained with sufficient understanding

Exclusion criteria

Exclusion criteria: 1) There is a disease that requires treatment, or the patient is under examination due to suspicion of the disease. 2) Have a history of blood disorders 3) History of blood transfusion or history of organ transplantation 4) Pregnant or within 1 year of delivery 5) History of the following infectious diseases (A) Malaria, Toxoplasma (B) Tuberculosis within 5 years after healing (C) Sexually transmitted diseases within 1 year after healing (D) Dengue fever within 1 month after healing (E) Onset of erythema infectiosum in the person within 6 months after healing or onset in the family within 1 month 6) Anyone judged inappropriate by the doctor

Design outcomes

Primary

MeasureTime frame
Ex vivo cell proliferation assays are performed on peripheral blood mononuclear cells of healthy volunteers.

Secondary

MeasureTime frame
If necessary, using peripheral blood mononuclear cell samples treated with drugs, changes in gene expression, histone modification and open chromatin regions will be assesed by RNA-seq, ChIP-seq and ATAC-seq.

Countries

Japan

Contacts

Public ContactYoshiro Hirasaki

Graduate School of Medicine, Chiba university Department of Japanese-Oriental (Kampo) Medicine

hrskyshr@chiba-u.jp043-226-2984

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026